| Literature DB >> 31527457 |
Anna Strunecka1, Otakar Strunecky2.
Abstract
The continuous rise of autism spectrum disorder (ASD) prevalent in the past few decades is causing an increase in public health and socioeconomic concern. A consensus suggests the involvement of both genetic and environmental factors in the ASD etiopathogenesis. Fluoride (F) is rarely recognized among the environmental risk factors of ASD, since the neurotoxic effects of F are not generally accepted. Our review aims to provide evidence of F neurotoxicity. We assess the risk of chronic F exposure in the ASD etiopathology and investigate the role of metabolic and mitochondrial dysfunction, oxidative stress and inflammation, immunoexcitotoxicity, and decreased melatonin levels. These symptoms have been observed both after chronic F exposure as well as in ASD. Moreover, we show that F in synergistic interactions with aluminum's free metal cation (Al3+) can reinforce the pathological symptoms of ASD. This reinforcement takes place at concentrations several times lower than when acting alone. A high ASD prevalence has been reported from countries with water fluoridation as well as from endemic fluorosis areas. We suggest focusing the ASD prevention on the reduction of the F and Al3+ burdens from daily life.Entities:
Keywords: ASD prevalence; aluminum; autism spectrum disorder; chronic fluoride exposure; endemic fluorosis; immunoexcitotoxicity; neurotoxicity; socioeconomic status; water fluoridation
Mesh:
Substances:
Year: 2019 PMID: 31527457 PMCID: PMC6765894 DOI: 10.3390/ijerph16183431
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Patients with autism spectrum disorder (ASD) have increased levels of blood lactate, alanine, and glutamate. LDH—lactate dehydrogenase; ALT—alanine transaminase.
Figure 2Amplification of signaling pathways by AlF4−. Its message is greatly amplified during the conversion into the functional response of a cell. Effector enzymes are adenylyl cyclase or phospholipase C. The second messenger molecule could be cAMP, inositol 1,4,5- trisphosphate, and diacylglycerol.
Figure 3The glutathione redox system. Glutathione (GSH), a radical scavenger, is converted to oxidized glutathione (GSSG) through GSH peroxidase (GPx) and converted back to GSH by GSH reductase (GR). GSH can detoxify hydrogen peroxide (H2O2), preventing the formation of free radical generation and lipid peroxidation products.
Figure 4Methylation and transsulfuration metabolism in ASD. SAM—S-adenosyl methionine, SAH—S-adenosylhomocysteine, GSH—glutathione, GSSG—oxidized glutathione, ATP—adenosine triphosphate.
Figure 5Serotonin is converted to melatonin in dark through the action of two enzymes: serotonin N-acetyltransferase and hydroxyindole O-methyltransferase. F inhibits hydroxyindole O-methyltransferase [47].
Figure 6Most important physiological actions of melatonin. Reducing the level of melatonin, F (in yellowgreen) interferes with all indicated events. Image used from Wikimedia Commons according to GNU Free Documentation License.
Current ASD prevalence in countries with water fluoridation.
| Country Year | Prevalence per 10,000 | This is 1 in X Children | Water Fluoridation% of Population | Reference |
|---|---|---|---|---|
| US 2014 | 169 | 1:59 | 70% for 70 y | [ |
| US 2016 | 250 | 1:40 | 70% for 70 y | [ |
| Canada 2018 | 152 | 1:66 | 45% for 12 y | [ |
| New Zealand 2016 | 152 | 1:66 | 62% for 50 y | [ |
| Australia 2015 | 144 | 1:150 | 80% for 35 y | [ |
ASD prevalence in countries with endemic fluorosis.
| Country Year | Prevalence per 10,000 | This is 1 in X Children | Reference |
|---|---|---|---|
| Bangladesh 2016 | 15; 80 | 1:666; 1:125 | [ |
| Dhaka 2016 | 300 | 1:33 | [ |
| China 2013–2016 | 19; 42 | 1:526; 1:238 | [ |
| China 2016 | 429; 530 | 1:23; 1:19 | [ |
| China 2013 Jilin | 108 | 1:92.5 | [ |
| Japan | 161 | 1:62 | [ |
| Japan 2018 | 322 | 1:31 | [ |
| India 2016 | 9 | 1:1111 | [ |
| India 2017 | 23 | 1:435 | [ |
| South Korea 2011 | 220 | 1:45 | [ |
| Sri Lanka 2016 | 93 | 1:107 | [ |
The ASD prevalence in the EU member states according to the available last reports.
| Country | Prevalence per 10,000 | This is 1 in X Children | Reference |
|---|---|---|---|
| EU total 2015–2018 | 44–197, average 122 | 1:82 | [ |
| Belgium | 60 | 1:167 | [ |
| Czech Republic | 12 | 1:833 | (pers. comm.) |
| Denmark | 34; 68 | 1:294; 1:147 | [ |
| Finland | 77 | 1:130 | [ |
| France | 27; 36 | 1:370; 1:277 | [ |
| Germany | 38 | 1:263 | [ |
| Ireland | 150 | 1:66 | [ |
| Italy Pisa | 86 | 1:116 | [ |
| Netherland | 57, 84 | 1:175; 1:119 | [ |
| Northern Ireland | 290 | 1:35 | [ |
| Norway | 12; 70 | 1:833; 1:142 | [ |
| Poland | 3 | 1:3333 | [ |
| Portugal | 9.2 | 1:1086 | [ |
| Spain | 13; 100 | 1:769; 1:100 | [ |
| Sweden | 71; 115 | 1:141; 1:87 | [ |
| UK | 100 | 1:100 | [ |
Adequate intake (AI) and upper tolerable intake levels (UL) for F (in mg/day). According to the National Academies of Sciences, Engineering, and Medicine, US [101]; NHMRC, Australia and New Zealand [102]; and EFSA, EU [103].
| Age | US | Australia, NZ | EU | |||
|---|---|---|---|---|---|---|
| AI | UL | AI | UL | Age | AI | |
| 0–6 m | 0.01 | 0.7 | – | 1.2 | 0–6 m | – |
| 7–12 m | 0.5 | 0.9 | 0.5 | 1.8 | 7–11 m | 0.4 |
| 1–3 y | 0.7 | 1.3 | 0.6 | 2.4 | 1–3 y | 0.6 |
| 4–8 y | 1.0 | 2.2 | 1.1 | 4.4 | 4–6 y | 1.0 |
| 9–13 y | 2.0 | 10 | 2.0 *; 3.0 + | 10 | 7–10 y | 1.5 |
| 14–18 y | 3.0 | 10 | 2.0 *; 3.0 + | 10 | 11–14 y | 2.2 |
| Males | 4.0 | 10 | 4.0 | 10 | 15–17 y | 3.2 |
| Adult females | 3.0 | 10 | 3.0 | 10 | Adults | 3.4 |
The following reference body weights were used when the AI and UL were expressed in mg F/day: 0–6 months, 6 kg; 7–12 months, 9 kg; 1–3 years, 12 kg; 4–8 years, 22 kg; 9–13 years, 40 kg; boys aged 14–18 years, 64 kg; 14–18 year-old girls, 57 kg; 76 kg for adult men; and 61 kg for adult women. * girls, + boys.